CELEX: 62015TB0269
Language: en
Date: 2019-05-15 00:00:00
Title: Case T-269/15: Order of the General Court of 15 May 2019 — Novartis Europharm v Commission (Medicinal products for human use — Marketing authorisation for the medicinal product Vantobra — tobramycine — Withdrawal of the contested measure — Action which has become devoid of purpose — No need to adjudicate)

22.7.2019   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 246/19
            
         
      Order of the General Court of 15 May 2019 — Novartis Europharm v Commission
      (Case T-269/15) (1)
      
      (Medicinal products for human use - Marketing authorisation for the medicinal product Vantobra - tobramycine - Withdrawal of the contested measure - Action which has become devoid of purpose - No need to adjudicate)
      (2019/C 246/19)
      Language of the case: English
      
         Parties
      
      
         Applicant: Novartis Europharm Ltd (Camberley, United Kingdom) (represented by: C. Schoonderbeek, lawyer)
      
         Defendant: European Commission (represented by: M. Šimerdová, A. Sipos and K. Mifsud-Bonnici, acting as Agents)
      
         Intervener in support of the defendant: Pari Pharma GmbH (Starnberg, Germany) (represented by: M. Epping and W. Rehmann, lawyers)
      
         Re:
      
      Application based on Article 263 TFEU seeking annulment of Commission Implementing Decision C(2015) 1977 final of 18 March 2015 granting marketing authorisation for the medicinal product for human use Vantobra — tobramycine, in accordance with Regulation No 726/2004 of the European Parliament and of the Council,
      
         Operative part of the order
      
      
                  1.
               
               
                  
                     There is no longer any need to adjudicate on the present action.
                  
               
            
                  2.
               
               
                  
                     Novartis Europharm Ltd shall bear its own costs and pay those incurred by the European Commission.
                  
               
            
                  3.
               
               
                  
                     Pari Pharma GmbH shall bear its own costs.
                  
               
            
         (1)  OJ C 279, 24.8.2015.